18,030,000-share swap for warrant by Inhibikase Therapeutics, Inc. (IKT)
Rhea-AI Filing Summary
Inhibikase Therapeutics, Inc. ten percent owner RA Capital Healthcare Fund, L.P. entered an Exchange Agreement on July 29, 2026, swapping 18,030,000 shares of Common Stock for a Pre-Funded Warrant exercisable for up to 18,030,000 shares at $0.001 per share. After this disposition, the Fund holds 6,970,000 shares of Common Stock. The Pre-Funded Warrant is immediately exercisable, has no expiration date, and includes a 9.99% beneficial ownership limitation for the Fund and its Attribution Parties. RA Capital Management, L.P., its general partner and principals Peter Kolchinsky and Rajeev Shah are also reporting persons and each disclaims beneficial ownership beyond respective pecuniary interests.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 18,030,000 shares
Net Sell
2 txns
Insider
RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.
Role
10% Owner | 10% Owner | 10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Pre-Funded Warrant (Right to Buy) F1, F4, F2, F3 | 18,030,000 | -- | -- |
| Other | Common Stock F1, F2, F3 | 18,030,000 | -- | -- |
Holdings After Transaction:
Pre-Funded Warrant (Right to Buy) — 18,030,000 shares (Indirect, See footnotes);
Common Stock — 6,970,000 shares (Indirect, See footnotes)
Footnotes (4)
- F1. On July 29, 2026, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 18,030,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 18,030,000 shares of the Issuer's Common Stock at an exercise price of $0.001 per share (the "Pre-Funded Warrant").
- F2. RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
- F3. Held directly by the Fund.
- F4. The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the Fund shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Fund, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
Key Figures
Common shares exchanged: 18,030,000 shares
Pre-Funded Warrant underlying shares: 18,030,000 shares
Pre-Funded Warrant exercise price: $0.001 per share
+2 more
5 metrics
Common shares exchanged
18,030,000 shares
Shares of Common Stock exchanged on July 29, 2026 under the Exchange Agreement
Pre-Funded Warrant underlying shares
18,030,000 shares
Maximum number of Common shares exercisable under the Pre-Funded Warrant
Pre-Funded Warrant exercise price
$0.001 per share
Exercise price for each share of Common Stock under the Pre-Funded Warrant
Common shares held after transaction
6,970,000 shares
Common Stock held by RA Capital Healthcare Fund, L.P. following the exchange
Beneficial ownership limitation
9.99% of outstanding Common Stock
Cap on aggregate Common Stock beneficially owned by the Fund and Attribution Parties after warrant exercise
Key Terms
Pre-Funded Warrant, Exchange Agreement, Attribution Parties, pecuniary interest
4 terms
Pre-Funded Warrant financial
"exchanged, for no additional consideration, 18,030,000 shares ... for a pre-funded warrant exercisable"
A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.
Exchange Agreement financial
"entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged"
A written deal in which two parties agree to swap assets, securities or obligations under set terms—think of it as a formal swap or trade contract. For investors it matters because such agreements can change who owns what, alter a company’s capital structure, affect future cash flows or dilute existing shares, and therefore influence value and risk in a straightforward, contract-driven way.
Attribution Parties regulatory
"together with its Attribution Parties ... to exceed 9.99% of the total number"
pecuniary interest financial
"disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What transaction was reported in Inhibikase Therapeutics (IKT)'s latest Form 4?
RA Capital Healthcare Fund, L.P. exchanged 18,030,000 Inhibikase Common shares for a Pre-Funded Warrant exercisable for up to 18,030,000 shares at $0.001 per share. This was done under an Exchange Agreement dated July 29, 2026 with Inhibikase Therapeutics, Inc.
What are the key terms of the Pre-Funded Warrant reported for Inhibikase Therapeutics (IKT)?
The Pre-Funded Warrant is exercisable immediately for up to 18,030,000 Common shares at an exercise price of $0.001 per share. It has no expiration date and is subject to a 9.99% cap on aggregate beneficial ownership including Attribution Parties.
Who are the reporting persons in the Inhibikase Therapeutics (IKT) Form 4 and how is ownership characterized?
Reporting persons are RA Capital Healthcare Fund, L.P., RA Capital Management, L.P., RA Capital Management GP, LLC principals Peter Kolchinsky and Rajeev Shah. Securities are held directly by the Fund, while others disclaim beneficial ownership except for their respective pecuniary interests.
Is there a beneficial ownership limit tied to the Pre-Funded Warrant for Inhibikase Therapeutics (IKT)?
Yes. The Fund cannot exercise the Pre-Funded Warrant if doing so would cause it and its Attribution Parties to beneficially own more than 9.99% of Inhibikase’s outstanding Common Stock following such exercise, effectively capping post-exercise ownership.
Were the Inhibikase Therapeutics (IKT) Form 4 transactions made under a Rule 10b5-1 trading plan?
The Form 4’s Rule 10b5-1 checkbox is not marked and the footnotes do not describe any Rule 10b5-1 or similar trading plan. The exchange appears as a negotiated transaction via an Exchange Agreement rather than a pre-set trading program.